Hepatitis E virus infections can be life threatening and transmitted through blood products

April 12, 2018, European Association for the Study of the Liver

Hepatitis E virus (HEV) infection is once again in the spotlight, with two studies presented today at The International Liver Congress 2018 in Paris, France challenging the ideas that HEV infections are benign and self-limiting, and that blood-borne transmission is a rare event. Researchers from Hamburg and Hannover in Germany collaborating on these studies have demonstrated that HEV infections can be fatal in immunocompromised, and in some cases, immune-competent individuals. They also demonstrated that blood products are an important source of infection in those who are immunosuppressed.

Hepatitis E virus is one of the leading causes of acute viral hepatitis worldwide, with two main genotypes (genotypes 1 and 3) affecting humans.10 Genotype 1 predominates in low-income countries and is transmitted via the faecal-oral route, while genotype 3 predominates in high-income countries and has been linked to the consumption of contaminated pork or shellfish products.8 The reported incidence of HEV infection has been increasing steadily across Europe, with more than 21,000 cases reported in a recently evaluated decade (2005-2015).

In a large observational study presented this week in Paris, 150 HEV RNA-positive individuals were identified retrospectively from the records of two tertiary referral hospitals and transplant centres in Northern Germany. Of the 69 immune-competent individuals identified, 37 (53%) were hospitalized for a total of 74 days, and two of these individuals who had preexisting liver disease died after developing acute-on-chronic liver failure. Eight (10%) immunosuppressed patients died within 5 years of being diagnosed with HEV infection, with three of these deaths considered to be related to the HEV infection.

"We have shown in this study that HEV infection can be associated with significant morbidity and mortality, and that a severe disease course is not limited to those who are immunocompromised," said Dr. Sven Pischke from the University Hospital Hamburg-Eppendorf in Germany. "Based on these findings, we urge all hepatologists to consider HEV as a differential diagnosis in any patient who presents with acute-on-chronic liver failure."The second study involved a retrospective analysis of data from 37 immunosuppressed patients with HEV infection. Eleven of these patients (30%) developed chronic HEV infection and, in four of these individuals (36%), the source of infection could be traced to an HEV-positive blood donation. Two of these patients were heart transplant recipients who had been treated with a combination of plasmapheresis and rituximab for humoral rejection.

"The number of notified transfusion-transmitted HEV infections has so far been relatively low, probably due to under-reporting and under-recognition," said Dr. Dirk Westhölter from the University Hospital Hamburg-Eppendorf, who presented the study findings today. "This study confirms that blood products are an important source of HEV infection for immunosuppressed and it has led us to recommend HEV RNA screening of all blood products destined for transplant or immunosuppressed patients."

"Both studies emphasize the severity of hepatitis E virus infection in vulnerable patients," said Prof. Markus Cornberg from the Hannover Medical School, Germany, and EASL Governing Board Member. "Acute infection needs to be prevented by all measures in patients with advanced liver disease, and in immunocompromised . Blood products can be an important source of transmission. These studies will lead to further discussions around if and how HEV screening of products should be carried out."

Explore further: Blood donor screening for hepatitis E reveals incidence is higher than previously reported

Related Stories

Blood donor screening for hepatitis E reveals incidence is higher than previously reported

April 21, 2017
Results from a study presented today found that the incidence of HEV RNA in asymptomatic blood donors from Germany is higher than previously reported. The study, presented at The International Liver Congress 2017 in Amsterdam, ...

Punjab, India: Mass treatment of a population with chronic hepatitis C infection produces high rates of cure

April 12, 2018
A large-scale study evaluating the feasibility of decentralized care and the provision of free direct-acting antiviral agents (DAAs) has reported high rates of cure among a population of almost 20,000 individuals completing ...

Alcoholic liver disease replaces hepatitis C infection as the leading cause of liver transplantation

April 11, 2018
Two independent studies have today reported that alcoholic liver disease has now replaced hepatitis C virus (HCV) infection as the leading cause of liver transplantation in the USA in patients without HCC. Non-alcoholic steatohepatitis ...

Italy: Ongoing hepatitis A virus outbreak among men who have sex with men is linked to current outbreaks in Europe

April 12, 2018
Hepatitis A viruses (HAVs) circulating in an ongoing outbreak among men who have sex with men (MSM) in the Lombardy region of Italy are predominantly attributable to strains linked to two other recent outbreaks in Europe, ...

First real-world studies report glecaprevir/pibrentasvir to be effective and well tolerated in chronic HCV infection

April 12, 2018
The results of the first real-world studies assessing the effectiveness and safety of glecaprevir/pibrentasvir (G/P) in patients with chronic hepatitis C virus (HCV) infection have confirmed high rates of viral suppression ...

A third of bacterial infections in patients with cirrhosis across the world are multi-drug resistant

April 12, 2018
A worldwide study initiated to investigate the epidemiology and outcomes of bacterial infections in hospitalized patients with liver cirrhosis has reported a prevalence of multi-drug-resistant (MDR) bacteria of 34% and significant ...

Recommended for you

A new approach to developing a vaccine against vivax malaria

September 21, 2018
A novel study reports an innovative approach for developing a vaccine against Plasmodium vivax, the most prevalent human malaria parasite outside sub-Saharan Africa. The study led by Hernando A. del Portillo and Carmen Fernandez-Becerra, ...

Pre-clinical success for a universal flu vaccine offers hope for third generation approach

September 21, 2018
Researchers from the University of Oxford's Department of Zoology have demonstrated pre-clinical success for a universal flu vaccine in a new paper published in Nature Communications.

Researchers define possible molecular pathway for neurodegeneration in prion diseases

September 21, 2018
A new study has shed light on the mechanisms underlying the progression of prion diseases and identified a potential target for treatment.

Fighting a deadly parasite: Scientists devise a method to store Cryptosporidium, aiding vaccine research efforts

September 21, 2018
In May, just before one of the hottest summers on record, the U.S. Centers for Disease Control and Prevention issued a warning about diseases lurking in recreational water facilities like swimming pools and water playgrounds. ...

Scientists make significant discovery in the fight against drug-resistant tuberculosis

September 20, 2018
A team of scientists have identified a naturally occurring antibiotic that may help in the fight against drug-resistant Tuberculosis.

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.